FindTrial
Sign In

Prospective randomised evaluation of high-intensity chemotherapy with peripheral blood progenitor support in patients with high risk breast cancer

Prospective randomised evaluation of high-intensity chemotherapy with peripheral blood progenitor support in patients with high risk breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN62673495
Enrollment
Unknown
Registered
2002-08-19
Start date
1997-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

1. High Dose Arm: Induction chemotherapy with single agent doxorubicin (adriamycin), treatment to be repeated every 3 weeks for four cycles. Induction chemotherapy to be followed by high dose chemothe

Sponsors

Amgen Limited (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged >18 years (usually <55 years). 2. Histologically proven operable stage II or IIIA breast cancer with an involvement of at least four lymph nodes 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 4. Confirmed normal haematological and biochemical parameters 5. Free from overt metastatic disease 6. No other malignancy, except basal cell carcinoma of the skin or in-situ carcinoma of the cervix 7. Fit to receive treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Secondary

MeasureTime frame
Not provided at time of registration—

Primary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026